Show simple item record

dc.contributor.author DeVore, Adam David
dc.contributor.author Milano, Carmelo Alessio
dc.contributor.author Rogers, JG
dc.coverage.spatial China
dc.date.accessioned 2015-12-03T21:38:01Z
dc.date.issued 2014-11
dc.identifier http://www.ncbi.nlm.nih.gov/pubmed/25512902
dc.identifier acs-03-06-603
dc.identifier.issn 2225-319X
dc.identifier.uri http://hdl.handle.net/10161/11078
dc.description.abstract The past five years have seen remarkable growth in the use of durable, continuous flow left ventricular assist devices (LVAD) with associated improvements in mortality, quality of life, functionality and end-organ function. To sustain the growth of this important therapy, the LVAD community must now address key issues focused around the costs of LVAD care, refined patient selection, and reducing complications associated with this therapy. In this perspective piece, we discuss many of these issues.
dc.language eng
dc.relation.ispartof Ann Cardiothorac Surg
dc.relation.isversionof 10.3978/j.issn.2225-319X.2014.08.22
dc.subject Mechanical support
dc.subject advanced heart failure
dc.subject ventricular assist devices (VAD)
dc.title VAD therapy 20/20: moving beyond the myopic view of a nascent therapy.
dc.type Journal article
pubs.author-url http://www.ncbi.nlm.nih.gov/pubmed/25512902
pubs.begin-page 603
pubs.end-page 605
pubs.issue 6
pubs.organisational-group Clinical Science Departments
pubs.organisational-group Duke
pubs.organisational-group Duke Clinical Research Institute
pubs.organisational-group Institutes and Centers
pubs.organisational-group Medicine
pubs.organisational-group Medicine, Cardiology
pubs.organisational-group School of Medicine
pubs.organisational-group Surgery
pubs.organisational-group Surgery, Cardiovascular and Thoracic Surgery
pubs.publication-status Published
pubs.volume 3


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record